MedTrace Logo

Evaluation Study of L-T3 Utility in the Follow-up of Patients With Thyroid Cancer

NCT00223158 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2014-04-09

No results posted yet for this study

Summary

To compare the hypothyroid state in patients with thyroid cancer prepared either by placebo or L-T3 following L-T4 withdrawal in preparation for whole body scintigraphy. To evaluate the time needed for TSH elevation (\> 30 mUI/L) on placebo vs. L-T3.

Conditions

Interventions

DRUG

Liothyronine

Sponsors & Collaborators

  • Theramed co.

    collaborator UNKNOWN

  • Patrice Perron

    lead OTHER

Principal Investigators

  • Rébecca Leboeuf, MD · Université de Sherbrooke

  • Marie-France Langlois, MD · Université de Sherbrooke

  • Patrice Perron, MD · Université de Sherbrooke

  • André Carpentier, MD · Université de Sherbrooke

  • Jean Verreault, MD · Université de Sherbrooke

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-09-30
Primary Completion
2005-05-31
Completion
2005-05-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00223158 on ClinicalTrials.gov